KRYS · Krystal Biotech, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 3, 2026TL;DR. Krystal Biotech reported Q2 2026 global VYJUVEK revenue of $119.2 million (up 24% year-over-year), with 95% gross margin, $54.8 million in net income, and over $1.1 billion in cash. Reimbursement approvals in the U.S. surpassed 730 and the prescriber base expanded to over 640, while European launches continued with pricing discussions ongoing in Germany and France and launches in Italy and Spain expected before year-end. The clinical pipeline advanced with multiple registrational readouts slated for 2H 2026 and additional registrational study starts planned for 2027.
- + Global VYJUVEK revenue rose 24% year-over-year to $119.2 million with gross margin expanding to 95%.
- + Net income grew to $54.8 million ($1.85 basic / $1.79 diluted EPS) versus $38.3 million a year ago.
- + Cash and investments strengthened to over $1.1 billion.
- + U.S. reimbursement approvals surpassed 730 (above the 60% initial penetration target) and the prescriber base expanded to over 640 unique prescribers.
- + Multiple registrational data readouts are slated for 2H 2026 across IOLITE (KB803), EMERALD-1 (KB801), KYANITE-1 (inhaled KB707), and interim updates for KB407 and KB111.
- − G&A expenses rose to $39.9 million from $35.1 million year-over-year, driven by headcount and global commercial costs.
- − Reported European/Japan revenue was broadly flat sequentially due to a reserve provision tied to ongoing German pricing negotiations.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRYS
this stock
Krystal Biotech, Inc.
|
$10.24B | +34.9% | +33.9% | 43.4 | 10.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRYS | -2.7% | -8.6% | +28.7% | -7.5% | +34.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.0% | -8.7% | +16.6% | -6.9% | +23.1% |